Redeye strengthens its positive view of Avensia following a Q2 report beating our forecasts. Both sales and margins were significantly stronger than expected, and the numbers highlight that Avensia can also do well in a soft but stable market, supporting its ambitious financial targets. We raise our Base Case and forecasts.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/